Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by FredTheVoiceon Apr 07, 2022 11:39am
72 Views
Post# 34584393

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So anything good coming out soon

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So anything good coming out soonANALIA WROTE:
"Hi Fred, I think Palinc's input is always very realistic in all time and I appreciate his input a lot. I think he could be less in JFM's back and reply to his input with less emotions and sarcastics comment but we saw worse comment from others. I also like JFM but he is very wrong on one thing. He wont admit that in between news, there is a lot a companie can and should do for shareholders. He does not agree that shareprice should not only reflect the actual situation but also the possible outcomes, the guidances. Then on top of that, what should increase even higher SP is if news announced by the cie meet or surpass expectations and cie's guidances. Remember the basic. For the first share to be sold in the 90's TH had to provide a plan and expections and guidances and many argument that shows that the ACTUAL SITUATION at the time and the "POSSIBLE" FUTURE might profit the investment. Today, and for the last couple of years, TH is not taking any opportunity or is failing to communicate properly their actual plan and state and the benifit that can result out of it. I agree with many here that TH could have simply find a way to keep their shareholders on board, excited about a possible bright future. Many here provided many other similar cie that succeeded to keep their SP at a level that reflect the possible outcomes, not TH. I also agree that even if they come up with the homerun you are expecting in vain since 2018 that they are failing to fairly promote their work and this is costly to all of us sharehoders and may keep custing us $ in the future if they dont change their "strategy". SP should reflect parts of the future expectations from the companie. Maybe it does and we are all refusing to see it ?"

Thats a great and realistic post. 

Thanks,

FTV.
<< Previous
Bullboard Posts
Next >>